|
|
||||||||
1 Cooperative Research Centre for Tissue Growth and Repair, Child Health Research Institute, Women's and Children's Hospital, North Adelaide 5006; 2 Plastic and Reconstructive Surgery, University of Adelaide, Department of Surgery, The Queen Elizabeth Hospital, Woodville 5011; 4 Commonwealth Scientific and Industrial Research Organization Division of Human Nutrition, Adelaide BC 5000; and 3 Food Science Australia, Highett, Victoria 3190, Australia
| |
ABSTRACT |
|---|
|
|
|---|
The ability of single growth factors to promote healing of normal and compromised wounds has been well described, but wound healing is a process requiring the coordinated action of multiple growth factors. Only the synergistic effect on wound healing of combinations containing at most two individual growth factors has been reported. We sought to assess the ability of a novel milk-derived growth factor-enriched preparation [mitogenic bovine whey extract (MBWE)], which contains six known growth factors, to promote repair processes in organotypic in vitro models and incisional wounds in vivo. MBWE stimulated the contraction of fibroblast-populated collagen lattices in a dose-dependent fashion and promoted the closure of excisional wounds in embryonic day 17 fetal rat skin. Application of MBWE increased incisional wound strength in normal animals on days 3, 5, 7, and 10 and reversed the decrease in wound strength observed following steroid treatment. Wound histology showed increased fibroblast numbers in wounds from normal and steroid-compromised animals. These data suggest the mixture of factors present in bovine milk exerts a direct action on the cells of cutaneous wound repair to enhance both normal and compromised healing.
growth factor; wound healing; skin; fetal wound healing; fibroblast-populated collagen lattice
| |
INTRODUCTION |
|---|
|
|
|---|
THE TOPICAL APPLICATION OF several classes of growth
factors has been shown to enhance all aspects of wound repair,
including inflammation, matrix synthesis, wound contraction,
epithelialization, and tissue remodelling (6). Studies to date have
largely focussed on the effects of single recombinant growth factors,
including members of the fibroblast growth factor (FGF) (17, 30),
insulin-like growth factor (IGF) (22, 48), transforming growth factor
(TGF)-
(34, 38, 39), platelet-derived growth factor (PDGF) (17, 18,
39), and epidermal growth factor (EGF) (19) families, the interleukins
(26), and colony stimulating factor (24). Importantly, these factors
have been shown to reverse the healing deficit associated with diabetes
(17), steroid administration (38), cytotoxic therapy (25), infection
(24), radiation (9, 35), and ischemia (49). However, the
activity of these factors in promoting wound repair on the experimental
animal has not been reproduced in clinical studies of chronic wound
healing (43). Whereas there are several possible reasons for this
discrepancy, it now seems likely that the proinflammatory environment
of the chronic wound adversely affects the stability and activity of the applied growth factors (29, 50). Thus the ability of any single
factor to enhance the multiple aspects of wound repair to produce a
clinically significant outcome may be limited.
Several studies have now clearly shown that wound repair is the result
of the temporally coordinated local expression of multiple families of
growth factors and their receptors (5). It would therefore seem
reasonable to hypothesize that the application of mixtures of growth
factors to the healing wound may be more effective than the addition of
a single factor. Indeed, several studies have shown this to be the
case. In particular, PDGF interacts with IGF-I (27), IGF-II (16), EGF,
and TGF-
(25), insulin (18), and TGF-
(7) to promote the repair
of a variety of wounds. EGF and insulin act synergistically to promote
collagen synthesis in the diabetic rat (19). Similarly, coapplication of IGF-I and its binding proteins is more effective at promoting wound
repair than application of IGF-I alone (22, 33).
Bovine milk is a rich source of several classes of growth factors,
including PDGF (46), IGF-I and -II (11), and TGF-
(21). We have
reported that cation-exchange fractionation of bovine whey results in a
100- to 200-fold enrichment of the growth factor activity present in
milk (10). The resultant fraction, mitogenic bovine whey extract
(MBWE), was shown to stimulate the growth of cells of mesodermal
origin, although, due to its TGF-
content, was found to be
inhibitory to the division of epithelial cells (3, 45). This fraction
also contains significant concentrations of IGF-I and -II, IGF binding
proteins 2 and 3, PDGF, and FGF-1 and -2, although together these known
growth factors account for only 50% of growth activity present (2,
44). Maximal growth of fibroblast lines in response to MBWE
significantly exceeded that in the presence of several individual
recombinant factors including PDGF, IGF-I, TGF-
, FGF-2, or EGF (3).
The aim of the current study was to investigate the wound repair activity of the milk-derived growth factor mixture. In vitro organotypic models initially were used to characterize the tissue repair activity of MBWE, and an in vivo model of incisional wound healing was used to assess the ability of MBWE to promote cutaneous repair in normal animals and reverse the deficit in healing associated with steroid administration.
| |
MATERIALS AND METHODS |
|---|
|
|
|---|
Materials
Human diploid skin fibroblasts (SF) were provided by the Women's and Children's Hospital (North Adelaide, Australia) and DMEM obtained from Flow Laboratories (Irvine, Scotland). Fetal bovine serum (FBS) was obtained from Cytosystems (Castle Hill, Australia) and [3H]inulin (1.18 Ci/mmol) from Amersham (Buckinghamshire, UK).Male Sprague-Dawley rats (250-300 g) were purchased from the University of Adelaide. All experiments were approved by the appropriate institutional animal care and ethics committee of the Women's and Children's Hospital, The Queen Elizabeth Hospital, or CSIRO Human Nutrition following the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes. Methylprednisolone (DepoMedrol, 20 mg/ml) was purchased from Upjohn (Rydalmere, New South Wales, Australia). Fluothane anesthetic (Halothane) was obtained from ICI Australia (Victoria, Australia) and used in combination with oxygen and nitrous oxide (BOC Gases, South Australia, Australia). Collagen was extracted from rat tail tendons in a solution of 0.1% acetic acid according to the method of Bell et al. (4). Before use as a vehicle matrix, the collagen was diluted in sterile water to a final concentration of 1 mg/ml and brought to neutrality with phosphate-buffered saline and NaOH.
Production of MBWE
Fractionation of whey was carried out as previously described (10). Briefly, pasteurized whey obtained as a byproduct of cheese manufacture was clarified by passage through a 0.8-µm ceramic filter (Membralox, Bajet, France). The ultrafiltrate was adjusted to pH 6.5 and applied to a 30-cm diameter column (Moduline, Beverly, MA) packed with 5 l of S-Sepharose Fast Flow cation-exchange resin (AMRAD Pharmacia Biotech, Victoria, Australia) equilibrated with 50 mM sodium citrate buffer at pH 6.5. After washing the column with the same buffer, the absorbed material was eluted with 0.5 M NaCl. This eluate was desalted, concentrated, and freeze dried. Growth activity was confirmed using a dye-binding cell growth assay as previously described (3). TGF-
concentration was determined using an Mv1Lu cell bioassay
(45). IGF-I concentration was measured by radioimmunoassay after
removal of IGF binding proteins by acid gel-permeation HPLC (37). MBWE
was screened for bovine diarrhea virus, infectious bovine
rhinotracheitis, parainfluenza type 3 and coliforms. Endotoxin levels
were also measured (Limulus Amebocyte Lysate assay, BioWhittaker,
Walkersville, MD).
Fibroblast-Populated Collagen Lattice Contraction
Human diploid SF were maintained in DMEM supplemented with penicillin (60 mg/l), streptomycin (100 mg/l), fungizone (1 mg/l), and 10% FBS. Stock cultures were maintained in 75-cm2 flasks (Corning, NY) in 5% CO2-95% air at 37°C and routinely passaged after suspension in trypsin (0.125%)/EDTA (0.5 mM) in Dulbecco's phosphate buffered saline.A solution of rat tail collagen (2 mg/ml) was mixed with an equal
volume of 2× DMEM at 4°C before addition of human SFs
(200,000 cells/ml final concentration) and
[3H]inulin (to 30,000-40,000
counts · min
1 · ml
1).
Five-hundred microliters of this solution were poured into each well of
a 48-place tissue culture plate (Costar, Cambridge, MA) and allowed to
set by incubation at 37°C for 30 min. Gels were freed from the
surrounding tissue culture plastic by rimming the margin with a
25-gauge needle. Dilutions of MBWE were applied to the top of the gels,
which were then maintained in a humidified atmosphere of
5%CO2-95% air at 37°C. Control wells containing either serum-free or FBS-supplemented medium were incorporated on each
plate. Fibroblast-induced contraction was assessed by counting the
radioactivity remaining in the gel after 24-h culture. Data were fit to
a four-parameter equation with the aid of a nonlinear curve-fitting
program (Tablecurve, Jandel Scientific, San Rafael, CA).
Fetal Skin Organ Culture
Wounding and culture of fetal rat skin were undertaken as previously described (1). Pregnant rats were killed by CO2 asphyxiation, the fetuses (E16-E17) removed from the uterus, weighed, and placed in Hank's balanced salt solution. A 1 × 1-cm piece of skin was dissected from the back of each fetus and a 1-mm diameter wound created in each explant using a squared-off, sharpened 19-gauge needle. The wound margin was marked by dipping the cutting needle into Indian ink immediately before wounding. The wounded skin was then mounted on a six-pin cradle and placed in a 12-well tissue-culture dish (Costar). After three washes with medium, serum-free DMEM or DMEM/MBWE (2.5 mg/ml) was added in a final volume of 2 ml. Wounds were photographed using a standard focal length jig at the time of culture and at 24, 48, and 72 h. Wound area was calculated by tracing the wound margin onto acetate sheets which were then scanned into a computer (Apple Macintosh Onscanner connected to an Apple Macintosh LCIII) equipped with an image analysis program (Prismview, Dapple Systems, Sunnyvale, CA). For histology, cultures were fixed in methacarn for 2 h before storage in 70% alcohol and processing by graded dehydration. Skin pieces were embedded vertically in wax blocks and 3-µm sections taken through the wound. Sections were stained with hematoxylin and eosin, viewed, and photographed.Incisional Wound Healing Model
Ability to promote repair of an incisional wound was investigated as previously described (34, 38). After induction of general anesthesia by inhalation of halothane, paired 6-cm incisions were created through the panniculus carnosis either side of the midline on the dorsal surface of the rat using a standard template. MBWE was dissolved in the collagen vehicle at the indicated concentrations and a single 200-µl dose of this formulation applied to one wound. The same volume of collagen vehicle was applied to the contralateral wound. The collagen was noted to cover the wound surface and gelled within 1-2 min. Left- and right-sided wounds were randomized with respect to treatment and were closed using five sutures (4/O silk, Dyneck, South Australia, Australia). Care was taken during suturing to evert the wound margins to ensure dermal-dermal contact along the length of the wound. All rats were housed individually after surgery and were weighed the day after surgery and then every 2 days. At various time points after wounding, rats were killed by CO2 asphyxiation and the pelts carefully removed. A standard template was used to cut four strips of 0.5-cm width through each wound (i.e., 1 strip through each of the wound segments bordered by two sutures, excluding the top and bottom wound margins) and either peak breaking strength measured using a M1000E (Mecmesin, West Sussex, UK) tensiometer (time-course study) or a breaking profile of each strip generated using a PCM2500EL tensiometer (Mecmesin) connected to a personal computer (dose-response study). The latter allowed calculation of peak load, yield load (defined as the point at which the gradient change in load over a set displacement interval becomes <20% of the calculated start gradient), force absorbed to yield load, and force absorbed to peak load.Histology
Samples of MBWE and collagen-treated wounds were collected and placed in 10% Formalin fixative immediately after harvesting and processed by graded dehydration. Three sections (3 µm) were cut through each wound, stained with hematoxylin and eosin, and scored by two independent observers (blinded). Each section was scored for mononuclear cell and fibroblast infiltration. Scores of zero to four were recorded for each section, and the average of three sections from each scorer was used to obtain an average score for the wound, which was used to calculate overall group means.Data Analysis
Five percent of strips in the steroid-treated group showed evidence of hemorrhage or dehiscence before dissection and were removed from the wound strength data set. Similarly, spontaneous separation of the dermal margins of the wound during processing for tensiometry (i.e., once they had been removed from the support of the sutures) was recorded as dehiscence, and the strip was excluded from wound-strength data analysis. All results are presented as means ± SE with wound-strength data analyzed using Student's t-test (dose-response study) or paired t-test (time-course study). Histology scores were analyzed by Kruskall-Wallis one-way analysis of variance on ranks with multiple comparisons versus the control group (combined data) performed using Dunn's method. P < 0.05 was considered significant.| |
RESULTS |
|---|
|
|
|---|
Activity of MBWE
Cell growth activity of MBWE was confirmed using Balb/c 3T3 fibroblasts and SFs as previously described (3). Growth activity corresponding to that observed in 10% FBS for Balb/c 3T3 fibroblasts and SFs was achieved with 150 and 610 µg/ml MBWE, respectively. The batch of MBWE used in the current study contained 1.6 ng/mg active TGF-
and 61 ng/mg total TGF-
bioactivity as determined by Mv1Lu cell bioassay
before and after acid activation, respectively. The batch of MBWE also
contained 32 ng/mg IGF-I. The concentrations of other growth factors
known to be present in MBWE, including PDGF and FGF, were not routinely
determined. In addition, MBWE was shown to be free of all
microbiological contaminants tested and contained <1 ng/ml endotoxin.
Effect of MBWE on Fibroblast-Induced Gel Contraction
The ability of MBWE to stimulate growth of several fibroblast cell lines (3) led us to further examine its repair activity using organotypic models of wound healing. MBWE markedly stimulated fibroblast-induced gel contraction in a dose-responsive manner when applied to fibroblast-populated collagen lattices (FPCL; Fig. 1). The dose that exerts half-maximal effect above baseline in this assay over a series of similar experiments was 195 ± 44 µg/ml (mean ± SE; n = 3).
|
Effect of MBWE on Wound Closure in Organ Cultured Fetal Rat Skin
The effect of MBWE on wound repair was further examined using a fetal skin organ culture model. Skin harvested from E16-E17 rat embryos retains the ability to heal an excisional wound in serum-supplemented suspension culture (1) and allows the effect of agents with potential wound-healing activity to be evaluated in an organ culture model isolated from blood-borne or environmental factors. Wounded E16-17 rat skin cultures were established as described and cultured in DMEM alone or DMEM plus MBWE (2.5 mg/ml). In DMEM alone, wounds contracted to 35-40% of the original wounded area over 72 h, although they never completely closed (Fig. 2A, a and c) (1). Addition of MBWE to the medium promoted complete closure over the 72-h culture period (Fig. 2A, b and d). The contraction of wounds in skin explants treated with MBWE was greatly accelerated compared with skin incubated in DMEM alone (Fig. 2B). The wound areas of MBWE-treated explants at 24 and 48 h were 20 ± 10% and 2.8 ± 2.2% their original area, respectively (Fig. 2B, means ± SE of triplicate cultures). In agreement with a previous study (1), histology through the wound after 48 h in DMEM alone showed no evidence of epithelial or mesenchymal movement into the wound defect (Fig. 3A). In contrast, histology through healed wounds after 48 h in the presence of MBWE showed that final wound closure had been achieved by the movement of the epidermal layer over the wound edge to form a "plug" of epithelium between the dermal margins (Fig. 3B).
|
|
Time Course of Response to MBWE
To examine the ability of MBWE to stimulate wound healing in normal rats and determine the time course of this response, MBWE was formulated at 2.5 mg/ml, corresponding to a total dose of 0.5 mg/wound, and applied to linear incisions on the dorsum of adult rats. This concentration of MBWE has previously been shown to stimulate maximal growth of human SFs in vitro (3), although concentrations up to 5 mg/ml were tolerated by these cells without a significant decrease in the maximal growth response. Wound strength was assessed at days 3, 5, 7, 10, 14, 21, and 42 after wounding.The peak load tolerated by MBWE- and vehicle-treated wounds is shown in
Table 1. Highly significant increases in
wound strength in response to topical MBWE were seen on days 5, 7, and 10, corresponding to average increases of 44%,
28%, and 20% over control wounds, respectively. The strength of
MBWE-treated wounds on days 3 and 21 were increased an
average of 21% and 10% over control values, respectively. Breaking
strengths on days 14 and 42 were not significantly different from vehicle-treated controls.
|
Dose Response to MBWE
A series of studies aimed at determining the optimal dose and assessing the histological picture of the MBWE-treated wounds was undertaken using both normal and steroid-compromised animals. Steroid-treated rats received an intramuscular injection of methylprednisolone (15 mg/kg) immediately before surgery. MBWE was formulated at 10, 2.5, and 1.25 mg/ml, each wound therefore receiving a total of 2, 0.5, and 0.25 mg of MBWE, respectively. As the maximal response to MBWE in normal animals occurred 5 days after wounding and application of the extract, all wounds were harvested at this time point.Normal animals. The force absorbed by each strip harvested from
normal animals 5 days after wounding is shown in Fig.
4A. Both force absorbed to yield
load (not shown) and force absorbed to peak load were significantly
increased in wounds treated with 0.5 mg/wound MBWE compared with
vehicle-treated wounds. In addition, the yield load and peak load in
the MBWE-treated wounds were increased an average of 62% and 25% over
control wounds, respectively (data not shown). Application of either
0.25 or 2.0 mg/wound MBWE did not significantly alter wound strength.
|
Steroid-treated animals. Administration of methylprednisolone on the day of wounding induced an average 15% weight loss compared with an 8% weight gain in the normal group over the course of the experiment and significantly reduced all indices of wound strength. Yield load, peak load, force absorbed to yield load, and force absorbed to peak load of vehicle-treated wounds were decreased an average of 44%, 39%, 42%, and 39%, respectively, in the steroid animals (P < 0.0001 for all). Whereas only ~1-2% of all strips taken through wounds on normal animals showed any signs of dehiscence, 28% of strips cut through vehicle-treated wounds on steroid-treated rats disrupted before placement in the tensiometer. This degree of wound breakdown in the steroid-treated group was reduced to 13% in wounds treated with 0.5 mg/wound MBWE, whereas the dehiscence rate in wounds treated with 0.25 and 2.0 mg/wound MBWE was consistent at 21%. Wounds treated with the 0.5 mg/wound dose of MBWE also exhibited a significant increase in both the force absorbed to yield load (not shown) and force absorbed to peak load compared with vehicle-treated wounds (Fig. 4B). Indeed, 0.5 mg/wound MBWE increased the wound strength to levels recorded from normal control wounds (Fig. 4A). Furthermore, the values for both the yield load and peak load were increased an average of 60% above their vehicle-treated controls (data not shown). As observed with wounds from normal animals, application of either 0.25 or 2.0 mg of MBWE did not significantly affect the force absorbed by the wound compared with their vehicle-treated controls (Fig. 4B).
Wound histology. Representative sections taken through wound
samples from normal and steroid rats are shown in Fig.
5 with semiquantitative histology scores of
sections from all treatment groups presented in Fig.
6. Comparison of Fig. 5, A and
C, shows the difference in wound histology expected between
normal and steroid-treated rats, which is characterized by the marked
absence of cellular infiltrate and granulation tissue. Administration of methylprednisolone significantly reduced the scores, reflecting fibroblast and inflammatory cell infiltration by 46% and 34%, respectively (Fig. 6, A and B). Treatment with MBWE
increased the cellular infiltrate in wounds on both normal and
steroid-treated rats (Fig. 5, B and D). This response
to MBWE was most noticeable in sections from wounds on steroid-treated
animals, the degree of wound cellularity comparable with sections from
normal control wounds (compare Fig. 5, A and D). This
increase in cellularity was due to an influx of fibroblasts into the
wound, which was not accompanied by a heightened inflammatory response
(Fig. 6, A and B). Within the steroid-treated group,
all doses of MBWE significantly increased fibroblast numbers compared
with their vehicle-treated controls. In normal rats, wounds treated
with either 0.25 or 0.5 mg/wound MBWE showed a significant increase in
fibroblast score. MBWE had no significant effect on the inflammatory score in wounds on both normal and steroid-treated animals (Fig. 6B).
|
|
| |
DISCUSSION |
|---|
|
|
|---|
We previously showed that cation-exchange chromatography results in a
100- to 200-fold enrichment of the growth factor component of
bovine milk. Although consisting of only 0.5% of whey protein, it
contains the bulk of growth factor activity present in bovine milk
(10). Importantly, this fraction contains several growth factors and
their binding proteins (2) that have been shown by others to act in
synergistic fashion in the wound, including IGF-I and PDGF (27), IGF-II
and PDGF (16), and IGF-I and IGF binding protein 3 (33). In addition,
MBWE contains significant concentrations of members of the TGF-
family, with TGF-
1, a factor known to significantly enhance the
healing strength of an incisional wound (34). Approximately
85% of the TGF-
activity in MBWE is accounted for by TGF-
2,
which exists as an acid labile 80-kDa species consistent with the small
latent complex of TGF-
(45). In this regard, it is interesting to
note that some 30-40% of platelet-derived TGF-
is retained in
the clot as the small latent complex, where it may act as a
slow release form of the molecule during the wound repair process (15).
The activity of the growth factor-enriched milk-derived fraction in
promoting different aspects of tissue repair was investigated in the
first instance using in vitro organotypic models. The ability of
fibroblasts incorporated in a collagen gel to reorganize the collagen
fibers and cause gel contraction is considered the in vitro counterpart
of wound contraction in the adult mammal (4, 32). This phenomenon has
been found to be dependent on the trophic activity of FBS (14).
However, in the present study, MBWE was able to substitute for serum in
stimulating fibroblast-mediated collagen lattice contraction (Fig. 1).
MBWE-induced contraction was dose dependent, with the maximal effect
over 24 h found to be at least equivalent to that observed in
serum-supplemented culture (not shown). Given that the individual
growth factors EGF, PDGF, and basic FGF (bFGF) failed to stimulate FPCL
contraction (32), it would appear that the novel mixture of growth
factors contained within MBWE may account for the response observed in this assay, with IGF-I or TGF-
likely to be at least partly
responsible for the activity evident in MBWE (13, 41).
The assertion that a mixture of individual growth factors such as that
present in MBWE may be effective at stimulating tissue repair is
further supported by the ability of MBWE to promote wound closure in
organ-cultured fetal skin. Skin harvested from the E16-17
embryo is able to heal a wound in vitro by a combined process of
mesenchymal contraction and substrate-independent movement of the
epithelium over the dermal margins of the wound to effect final closure
(1). This repair response is dependent on the presence of serum but is
not promoted by the addition of single recombinant factors such as
IGF-I, EGF, bFGF, TGF-
, or PDGF. Although wound closure is likely to
result from the coordinated action of epithelial cells to mobilize
contractile proteins and close the wound by a purse-string mechanism
(28), the trophic requirement for this form of epithelial repair is
unknown. MBWE was able to substitute for serum in promoting wound
closure, histology clearly revealing the presence of epithelium
spanning the dermal margins of the wound (Fig. 3). Nevertheless, the
dermal margins were consistently more approximated after culture in
MBWE than in serum-supplemented cultures compared with previously
published results (1), possibly reflecting the action of the factors in
MBWE on the mesenchymal layer to enhance wound contraction. Thus the
mixture of factors contained in MBWE has the capacity to induce novel
effects on fetal wound closure that are not observed after application
of individual factors, suggesting that appropriate combinations of
growth factors may act in a coordinated fashion to stimulate the
sequence of events required for successful healing. We cannot, however,
rule out the possibility that an as yet unidentified molecule(s) may be
present in MBWE that has unique and singular effects on the repair process.
All surface wounds heal by a process of wound contraction, matrix synthesis and remodelling, and epithelialization. Apposition of the wound margins allows healing by primary intention, which is mainly achieved by matrix synthesis. Thus the ability of a topical agent to enhance the strength of an incisional wound reflects a direct or indirect ability to enhance wound fibroblast division, migration into the wound, or biosynthetic capacity. The ability of MBWE to promote wound repair was most evident in steroid-treated animals, suggesting a direct action of the growth factors in MBWE on the cells of wound repair. Steroid administration profoundly inhibits both the inflammatory response to wounding and the expression of procollagen genes by SFs (12). A single dose of methylprednisolone at or before wounding inhibits wound contraction (23), synthesis of granulation tissue, and angiogenesis and decreases wound strength (38). In the current study, all indices of wound strength were reduced by ~40% of control values 5 days after administration of methylprednisolone. The most effective dose of MBWE (0.5 mg/wound) returned the force absorbed by wounds on steroid-treated animals to levels observed in normal animals and resulted in a histological picture similar to that seen on sections from control wounds on normal animals.
The ability of MBWE to promote wound repair was concentration
dependent. Higher concentrations of MBWE promoted fibroblast influx but
did not increase the strength of incisional wounds on either the normal
or steroid-treated animals. Whereas we cannot rule out the presence of
some inhibitory activity in MBWE, it is possible this phenomenon is due
to the bimodal action of some individual growth factors in MBWE. Both
TGF-
and bFGF have been shown to have apparent
concentration-dependent bimodal effects on the strength of incisional
wounds in vivo (36, 39). Similarly, a bimodal effect of TGF-
and
bFGF on the volume of new granulation tissue detected in rabbit ear
excisional wounds has also been reported (40).
The possible complex interactions among the known growth factors in
MBWE render any discussion of its mechanism of action in the wound
somewhat speculative. Furthermore, it is impossible to rule out effects
on wound healing by components of MBWE that are not growth factors.
Moreover, although the activity of MBWE in steroid-treated rats would
suggest a direct action on the wound, we cannot exclude indirect
effects of the components of MBWE on the cells of wound repair.
Nevertheless, comparative studies using single growth factors may
provide some clues. PDGF, TGF-
, and FGF all stimulate granulation
tissue deposition. TGF-
1 in particular has been shown to act
directly on the cells of cutaneous healing to induce the fibrotic and
angiogenic components of repair in vivo (42). Thus TGF-
1 is
effective in promoting repair of wounds on animals rendered
monocytopenic by steroid administration (38) or total body irradiation
(9), although it is ineffective in rats whose dermal fibroblasts have
been damaged by surface irradiation (9). In contrast, PDGF does not
directly stimulate collagen synthesis (42) and cannot reverse the wound
healing deficit associated with circulating and wound monocytopenia as
a result of steroid treatment (38), although it was able to improve
wound repair in animals whose dermal fibroblasts had been damaged by surface irradiation by recruiting macrophages to the wound
(35).
The degree of improvement in wound strength observed in response to
MBWE 5 days after wounding steroid-treated rats is greater than that
reported following administration of recombinant TGF-
1 in a
comparable study (38), suggesting the potential synergistic action of
factors present in MBWE. In this regard, IGF-I and -II are also known
to promote fibroblast division (8), protein, collagen, and fibronectin
synthesis (20), and local administration of IGF-I has been shown to
reverse the effects of steroids on inhibition of granulation tissue
ingrowth to a subcutaneous chamber (48). Coadministration of IGF-I with
its binding proteins increases wound strength (22). Similarly, both
acidic and basic FGF have been shown to increase wound strength (30,
31). Indeed, Lynch et al. (27) found a combination of PDGF-2 and IGF-I
to be the most potent inducer for healing partial-thickness porcine
wounds compared with various other individual growth factors or
combinations tested.
Although some studies have shown the maximum wound strength achieved by
the application of single growth factors (principally TGF-
) to be
greater than that observed in our experiments, it should be noted that
comparative studies have generally added microgram quantities of single
recombinant growth factors to wounds (27, 34, 36, 39, 40). The amount
of individual growth factors applied to wounds treated with MBWE was in
the low nanogram range. It is possible further purification of MBWE
designed to concentrate specific growth factor components of the
extract may enhance the wound healing activity of these fractions.
The current report represents the first to describe the ability of a mitogenic extract containing the complement of growth factors present in milk to stimulate a healing response in organotypic wound models and promote healing of the incisional wound in vivo. Together with in vitro data showing significant activity in assays of cell growth (3, 10), our results would suggest the unique mix of agents in MBWE may confer an ability to promote wound repair over and above that obtained with single growth factors and that is particularly relevant to rectifying the healing deficits associated with compromised conditions resulting in chronic cutaneous wounds (47).
Perspectives
Wound healing is a complex series of events aimed at restoring the integrity of damaged tissue. Included in these events are the actions of growth factors, which play an essential role in directing wound repair. The action of such mediators, however, is disturbed in tissue compromised by lack of blood flow or systemic diseases such as diabetes, leading to failure of the cellular processes of healing. Whereas growth factors have been shown to enhance all aspects of wound repair in experimental models, the effectiveness of individual growth factors has generally been difficult to replicate when applied to clinical studies in chronic wounds. As wound repair results from the temporally coordinated local expression of multiple families of growth factors and their receptors, it would seem reasonable that the application of mixtures of growth factors to the healing wound may be more effective than a single factor. Bovine milk is a rich source of several classes of growth factors, and cation-exchange fractionation of bovine whey results in a mitogenic extract that contains a 100- to 200-fold enrichment of the growth factor activity present in milk. Our results demonstrate that this mitogenic extract derived from milk has considerable wound healing activity, and, given the mixture of growth factors present, we speculate that it may have potential as a clinical treatment to stimulate healing of chronic ulcers and other problem wounds. The socioeconomic benefits of such an agent that can effectively heal chronic wounds is likely to be substantial, given the morbidity and high cost of treatment of this often age-related problem.| |
ACKNOWLEDGEMENTS |
|---|
We thank Kaylene Pickering, Xenia Georgiou, Anna Seamark, Caroline Payne, and Sue Millard for technical assistance. Microbiological screening of MBWE was undertaken by the Victorian Institute of Animal Sciences.
| |
FOOTNOTES |
|---|
This work was supported by a grant from the Dairy Research and Development Corporation of Australia and the Cooperative Research Centre Scheme, Commonwealth Government of Australia.
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: T. E. Rayner, Child Health Research Institute, Women's and Children's Hospital, 72 King William Rd., North Adelaide 5006, SA, Australia (E-mail: trayner{at}medicine.adelaide.edu.au).
Received 3 June 1999; accepted in final form 3 December 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Belford, DA.
The mechanism of excisional fetal wound repair in vitro is responsive to growth factors.
Endocrinology
138:
3987-3996,
1997
2.
Belford, DA,
Rogers ML,
Francis GL,
Payne C,
Ballard FJ,
and
Goddard C.
Platelet-derived growth factor, insulin-like growth factors, fibroblast growth factors and transforming growth factor
do not account for the cell growth activity present in bovine milk.
J Endocrinol
154:
45-55,
1997
3.
Belford, DA,
Rogers ML,
Regester GO,
Francis GL,
Smithers GW,
Liepe IJ,
Priebe IK,
and
Ballard FJ.
Milk-derived growth factors as serum supplements for the growth of fibroblast and epithelial cells.
In Vitro Cell Develop Biol
31:
752-760,
1995.
4.
Bell, E,
Ivarsson B,
and
Merrill C.
Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro.
Proc Natl Acad Sci USA
76:
1274-1278,
1979
5.
Bennett, NT,
and
Schultz GS.
Growth factors and wound healing: biochemical properties of growth factors and their receptors.
Am J Surg
165:
728-737,
1993[Web of Science][Medline].
6.
Bennett, NT,
and
Schultz GS.
Growth factors and wound healing: II. Role in normal and chronic wound healing.
Am J Surg
166:
74-81,
1993[Web of Science][Medline].
7.
Brown, RL,
Breeden MP,
and
Greenhalgh DG.
PDGF and TGF-
act synergistically to improve wound healing in the genetically diabetic mouse.
J Surg Res
56:
562-570,
1994[Web of Science][Medline].
8.
Cook, JJ,
Haynes KM,
and
Werther GA.
Mitogenic effects of growth hormone in cultured human fibroblasts; evidence for action via local insulin-like growth factor I production.
J Clin Invest
81:
206-212,
1988.
9.
Cromack, DT,
Porras-Reyes B,
Purdy JA,
Pierce GF,
and
Mustoe TA.
Acceleration of tissue repair by transforming growth factor
1: identification of in vivo mechanism of action with radiotherapy-induced specific healing deficits.
Surgery
113:
36-42,
1993[Web of Science][Medline].
10.
Francis, GL,
Regester GO,
Webb HA,
and
Ballard FJ.
Extraction from cheese whey by cation-exchange chromatography of factors that stimulate the growth of mammalian cells.
J Dairy Res
78:
1209-1218,
1995.
11.
Francis, GL,
Upton FM,
Ballard FJ,
McNeil KA,
and
Wallace JC.
Insulin-like growth factors 1 and 2 in bovine colostrum: sequences and biological activities compared with those of a potent truncated form.
Biochem J
251:
95-103,
1988[Web of Science][Medline].
12.
Fuller, GC,
and
Cutroneo KR.
Pharmacological interventions.
In: Wound Healing Biochemical and Clinical Aspects, edited by Cohen IK,
Diegelmann RF,
and Lindblad WJ.. Philadelphia, PA: Saunders, 1992, p. 305-315.
13.
Gillery, P,
Leperre A,
Maquart FX,
and
Borel JP.
Insulin-like growth factor-I (IGF-I) stimulates protein synthesis and collagen gene expression in monolayer and lattice cultures of fibroblasts.
J Cell Physiol
152:
389-396,
1992[Web of Science][Medline].
14.
Gillery, P,
Maquart FX,
and
Borel JP.
Fibronectin dependence of the contraction of collagen lattices by human skin fibroblasts.
Exp Cell Res
167:
29-37,
1986[Web of Science][Medline].
15.
Grainger, DJ,
Wakefield L,
Bethell HW,
Farndale RW,
and
Metcalf JC.
Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin.
Nat Med
1:
932-937,
1995[Web of Science][Medline].
16.
Greenhalgh, DG,
Hummel RP, III,
Albertson S,
and
Breedon MP.
Synergistic actions of platelet-derived growth factor and the insulin-like growth factors in vivo.
Wound Rep Reg
1:
69-81,
1993[Medline].
17.
Greenhalgh, DG,
Sprugel KH,
Murray MJ,
and
Ross R.
PDGF and FGF stimulate wound healing in the genetically diabetic mouse.
Am J Pathol
136:
1235-1246,
1990[Abstract].
18.
Grotendorst, GR,
Martin GR,
Pencev D,
Sodek J,
and
Harvey AK.
Stimulation of granulation tissue formation by platelet-derived growth factor in normal and diabetic rats.
J Clin Invest
76:
2323-2329,
1985.
19.
Hennessey, PJ,
Black CT,
and
Andrassy RJ.
Epidermal growth factor and insulin act synergistically during diabetic healing.
Arch Surg
125:
926-929,
1990
20.
Ignotz, RA,
and
Massagué J.
Transforming growth factor-
stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix.
J Biol Chem
261:
4337-4345,
1986
21.
Jin, Y,
Cox DA,
Knecht R,
Raschdorf F,
and
Cerletti N.
Separation, purification, and sequence identification of TGF-beta 1 and TGF-beta 2 from bovine milk.
J Protein Chem
10:
565-575,
1991[Web of Science][Medline].
22.
Jyung, RW,
Mustoe TA,
Busby WH,
and
Clemmons DR.
Increased wound-breaking strength induced by insulin-like growth factor I in combination with insulin-like growth factor binding protein-1.
Surgery
115:
233-239,
1994[Web of Science][Medline].
23.
Karr, BP,
Bubak PJ,
Sprugel KH,
Pavlin EG,
and
Engrav LH.
Platelet-derived growth factor and wound contraction in the rat.
J Surg Res
59:
739-742,
1995[Web of Science][Medline].
24.
Kucukcelebi, A,
Carp SS,
Hayward PG,
Hui P,
Cowan WT,
Ko F,
Cooper DM,
and
Robson MC.
Granulocyte-macrophage colony stimulating factor reverses the inhibition of wound contraction caused by bacterial contamination.
Wounds
4:
241-247,
1992.
25.
Lawrence, WT,
Sporn MB,
Gorschboth C,
Norton JA,
and
Grotendorst GR.
The reversal of an adriamycin induced healing impairment with chemoattractants and growth factors.
Ann Surg
203:
142-147,
1985.
26.
LeGrand, EK,
Senter LH,
Gamelli RL,
and
Kiorpes TC.
Evaluation of PDGF-BB, PDGF-AA, bFGF, IL-1, and EGF dose responses in polyvinyl alcohol sponge implants assessed by a rapid histologic method.
Growth Factors
8:
315-329,
1993[Web of Science][Medline].
27.
Lynch, SE,
Colvin RB,
and
Antoniades HN.
Growth factors in wound healing: single and synergistic effects on partial thickness porcine skin wounds.
J Clin Invest
84:
640-646,
1989.
28.
Martin, P,
and
Lewis J.
Actin cables and epidermal movement in embryonic wound healing.
Nature
360:
179-183,
1992[Medline].
29.
Mast, BA,
and
Schultz GS.
Interactions of cytokines, growth factors and proteases in acute and chronic wounds.
Wound Rep Reg
4:
411-420,
1996.
30.
McGee, GS,
Davidson JM,
Buckley A,
Sommer A,
Woodward SC,
Aquino AM,
Barbour R,
and
Demetriou AA.
Recombinant basic fibroblast growth factor accelerates wound healing.
J Surg Res
45:
145-153,
1988[Web of Science][Medline].
31.
Mellin, TN,
Mennie RJ,
Cashen DE,
Ronan JJ,
Capparella J,
James ML,
DiSalvo J,
Frank J,
Linemeyer D,
Gimenez-Gallego G,
and
Thomas KA.
Acidic fibroblast growth factor accelerates dermal wound healing.
Growth Factors
7:
1-14,
1992[Medline].
32.
Montesano, R,
and
Orci L.
Transforming growth factor beta stimulates collagen-matrix contraction by fibroblasts: implications for wound healing.
Proc Natl Acad Sci USA
85:
4894-4897,
1988
33.
Mueller, RV,
Spencer EM,
Sommer A,
Maack CA,
Suh D,
and
Hunt TK.
The role of IGF-I and IGFBP-3 in wound healing.
In: Modern Concepts of Insulin-like Growth Factors, edited by Spencer EM.. New York: Elsevier, 1991, p. 185-192.
34.
Mustoe, TA,
Pierce GF,
Thomason A,
Gramates P,
Sporn MB,
and
Deuel TF.
Accelerated healing of incisional wounds in rats induced by transforming growth factor-
.
Science
237:
1333-1336,
1987
35.
Mustoe, TA,
Purdy J,
Gramates P,
Deuel TF,
Thomason A,
and
Pierce GF.
Reversal of impaired wound healing in irradiated rats by platelet-derived growth factor-BB.
Am J Surg
158:
345-350,
1989[Web of Science][Medline].
36.
Okumura, M,
Okuda T,
Nakamura T,
and
Yajima M.
Effect of basic fibroblast growth factor on wound healing in healing-impaired animal models.
Drug Res
46:
547-551,
1996[Medline].
37.
Owens, PC,
Johnson RJ,
Campbell RG,
and
Ballard FJ.
Growth hormone increases insulin-like growth factor-I (IGF-I) and decreases IGF-II in plasma of growing pigs.
J Endocrinol
124:
269-275,
1990
38.
Pierce, GF,
Mustoe TA,
Lingelbach J,
Masakowski VR,
Gramates P,
and
Deuel TF.
Transforming growth factor
reverses the glucocorticoid-induced wound-healing deficit in rats: possible regulation in macrophages by platelet-derived growth factor.
Proc Natl Acad Sci USA
86:
2229-2233,
1989
39.
Pierce, GF,
Mustoe TA,
Lingelbach J,
Masakowski VR,
Griffin GL,
Senior RM,
and
Deuel TF.
Platelet-derived growth factor and transforming growth factor-
enhance tissue repair activities by unique mechanisms.
J Cell Biol
109:
429-440,
1989
40.
Pierce, GF,
Tarpley JE,
Yanagihara D,
Mustoe TA,
Fox GM,
and
Thomason A.
Platelet-derived growth factor (BB homodimer), transforming growth factor-
1, and basic fibroblast growth factor in dermal wound healing.
Am J Pathol
140:
1375-1388,
1992[Abstract].
41.
Piscatelli, SJ,
Michaels BM,
Gregory P,
Jennings RW,
Longaker MT,
Harrison MR,
and
Siebert JW.
Fetal fibroblast contraction of collagen matrices in vitro: the effects of epidermal growth factor and transforming growth factor-beta.
Ann Plast Surg
33:
38-45,
1994[Web of Science][Medline].
42.
Roberts, AB,
Sporn MB,
Assoian RK,
Smith JM,
Roche NS,
Wakefield LM,
Heine UI,
Liotta LA,
Falanga V,
Kehrl JH,
and
Fauci AS.
Transforming growth factor type
: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro.
Proc Natl Acad Sci USA
83:
4167-4171,
1986
43.
Robson, MC.
The role of growth factors in the healing of chronic wounds.
Wound Rep Reg
5:
12-17,
1997.
44.
Rogers, ML,
Belford DA,
Francis GL,
and
Ballard FJ.
Identification of fibroblast growth factors in bovine cheese whey.
J Dairy Res
62:
501-507,
1995[Web of Science][Medline].
45.
Rogers, ML,
Goddard C,
Regester GO,
Ballard FJ,
and
Belford DA.
Transforming growth factor
in bovine milk: concentration, stability and molecular mass forms.
J Endocrinol
151:
77-86,
1996
46.
Shing, Y,
and
Klagsbrun M.
Purification and characterization of a bovine colostrum-derived growth factor.
Mol Endocrinol
1:
335-338,
1987
47.
Stadelmann, WK,
Digenis AG,
and
Tobin GR.
Physiology and healing dynamics of chronic cutaneous wounds.
Am J Surg
176, Suppl 2A:
26S-38S,
1998[Web of Science][Medline].
48.
Suh, DY,
Hunt TK,
and
Spencer EM.
Insulin-like growth factor-I reverses the impairment of wound healing induced by corticosteroids in rats.
Endocrinology
131:
2399-2403,
1992
49.
Uhl, E,
Barker JH,
Bondàr I,
Galla TJ,
Leiderer R,
Lehr HA,
and
Messmer K.
Basic fibroblast growth factor accelerates wound healing in chronically ischaemic tissue.
Br J Surg
80:
977-980,
1993[Web of Science][Medline].
50.
Yager, DR,
Chen SM,
Ward SI,
Olutoye OO,
Diegelmann RF,
and
Cohen IK.
Ability of chronic wound fluids to degrade peptide growth factors is associated with increased levels of elastase activity and diminished levels of proteinase inhibitors.
Wound Rep Reg
5:
23-32,
1997.
This article has been cited by other articles:
![]() |
G. W. Krissansen Emerging Health Properties of Whey Proteins and Their Clinical Implications J. Am. Coll. Nutr., December 1, 2007; 26(6): 713S - 723S. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Baba, A. Masuyama, and T. Takano Short communication: Effects of Lactobacillus helveticus-fermented milk on the differentiation of cultured normal human epidermal keratinocytes. J Dairy Sci, June 1, 2006; 89(6): 2072 - 2075. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |